CorVel (NASDAQ:CRVL) Shares Gap Up – What’s Next?
by Danessa Lincoln · The Markets DailyCorVel Corp. (NASDAQ:CRVL – Get Free Report)’s stock price gapped up prior to trading on Wednesday . The stock had previously closed at $57.60, but opened at $60.24. CorVel shares last traded at $60.81, with a volume of 3,204 shares changing hands.
Analysts Set New Price Targets
Several equities research analysts have recently issued reports on the stock. Wall Street Zen raised shares of CorVel from a “hold” rating to a “buy” rating in a research report on Saturday, May 30th. Weiss Ratings lowered CorVel from a “hold (c-)” rating to a “sell (d+)” rating in a report on Monday, April 6th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, CorVel has a consensus rating of “Sell”.
Check Out Our Latest Report on CorVel
CorVel Stock Up 2.8%
The stock has a fifty day moving average of $58.64 and a 200-day moving average of $59.48. The stock has a market capitalization of $3.11 billion, a price-to-earnings ratio of 28.74 and a beta of 0.99.
CorVel (NASDAQ:CRVL – Get Free Report) last released its quarterly earnings data on Tuesday, May 19th. The business services provider reported $0.61 earnings per share for the quarter. The company had revenue of $248.55 million for the quarter. CorVel had a net margin of 11.51% and a return on equity of 29.92%.
Insider Buying and Selling
In related news, VP Jennifer Yoss sold 1,999 shares of the business’s stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $61.02, for a total value of $121,978.98. Following the completion of the sale, the vice president directly owned 2,173 shares of the company’s stock, valued at $132,596.46. The trade was a 47.91% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Maxim Shishin sold 2,250 shares of the company’s stock in a transaction on Friday, June 12th. The shares were sold at an average price of $60.59, for a total transaction of $136,327.50. Following the completion of the transaction, the insider owned 7,050 shares of the company’s stock, valued at $427,159.50. This represents a 24.19% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 13,249 shares of company stock worth $807,126 in the last ninety days. 44.56% of the stock is owned by corporate insiders.
Institutional Trading of CorVel
A number of large investors have recently made changes to their positions in CRVL. Northwestern Mutual Wealth Management Co. acquired a new position in CorVel during the third quarter worth approximately $31,000. Los Angeles Capital Management LLC acquired a new stake in shares of CorVel in the fourth quarter valued at approximately $33,000. Eagle Bay Advisors LLC acquired a new stake in shares of CorVel in the fourth quarter valued at approximately $37,000. Rockefeller Capital Management L.P. grew its position in shares of CorVel by 66.9% during the fourth quarter. Rockefeller Capital Management L.P. now owns 574 shares of the business services provider’s stock worth $39,000 after acquiring an additional 230 shares during the last quarter. Finally, Quarry LP grew its position in shares of CorVel by 218.6% during the third quarter. Quarry LP now owns 513 shares of the business services provider’s stock worth $40,000 after acquiring an additional 352 shares during the last quarter. 51.36% of the stock is owned by institutional investors and hedge funds.
CorVel Company Profile
CorVel Corporation (NASDAQ: CRVL) is a technology-driven provider of workers’ compensation, liability, and specialty risk management solutions. The company develops and deploys software and data analytics tools to streamline claims administration, medical cost containment, prescription drug management, and provider network access. CorVel’s integrated platform connects employers, insurers, healthcare providers, and injured workers, aiming to improve outcomes and control costs through process automation and real-time decision support.
The company’s product suite includes claims lifecycle management, bill review and negotiation, virtual care and telehealth services, pharmacy benefit management, and independent medical examinations (IMEs).